Potential oral therapy in MS

Article

Oral resveratrol SRT501 significantly lowers neuronal damage, in a model of multiple scelrosis (MS).

A study published in the Journal of Neuro-Ophthalmology claims that oral resveratrol SRT501 significantly lowers neuronal damage, in a model of multiple scelrosis (MS).

It was found that the pharmaceutical grade formulation of SRT501 activated the NAD+ dependent deacetylase SIRT1 and encourages mitochondrial function.

Dr Kenneth S. Shindler, et al., Penn Presbyterian Medical Center, Philladelphia, USA, looked at the effect oral therapy SRT501, a pharmaceutical grade formulation of resveratrol, has on neuronal loss during relapse-remitting experimental autoimmune ancephalomyelititis (EAE). The therapy resveratrol is known to activate the NAD+ dependent deacetylase, SIRTI, which encourages mitochondrial function.

It was found that SRT501 prevented neuronal loss in optic neuritis and suppressed neurological dysfunction during EAE remission. The results also revealed that a SIRTI inhibitor, sirtinol, reduced the neuroprotective effects of SRT501 and other SIRTI activators gave similar results to SRT501.

It was concluded that resveratrol is effective in lowering neuronal damage in EAE through activation of SIRTI so therapies activating this deacetylase have potential as oral therapies in MS.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.